Levels of S100B are raised in female patients with schizophrenia

BMC Psychiatry

Kumlesh K Dev²  Jogin Thakore¹  Kara O’Connell¹ 

[1] Neuroscience Centre, St. Vincent’s Hospital Fairview, Fairview, Dublin, Ireland;Molecular Neuropharmacology, Department of Physiology, School of Medicine, Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland

关键词: Schizophrenia;    Metabolic syndrome;    Antipsychotics;    Clozapine;    S100B;   

Others  :  1124047
DOI  :  10.1186/1471-244X-13-146

 received in 2013-01-28, accepted in 2013-05-06,  发布年份 2013

【 摘 要 】

Background

The neurotrophic factor, S100B, is released primarily from astrocytes, with serum and CSF levels of S100B reported as altered in schizophrenia. However, many of these reports are contradictory. Here, serum levels of S100B in schizophrenia and influence of age, gender, medication and illness severity were examined.

Methods

Serum S100B levels were measured in patients with schizophrenia treated with clozapine. Lifestyle, metabolic and illness severity parameters were correlated with S100B concentrations.

Results

Data showed raised serum levels of S100B in schizophrenia female patients, but not male patients, compared to controls. Correlation analysis demonstrated a positive association between S100B serum concentrations and BMI.

Conclusions

This study supports previous findings that adipocytes may contribute to S100B serum concentrations in females, in addition to astrocytes. This study also supports the hypothesis that metabolic effects of medication, lifestyle choices and the illness itself, may be contributing factors to altered levels of S100B.

【 授权许可】

   
2013 O’Connell et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Steiner J, Bogerts B, Schroeter ML: S100B protein in neurodegenerative disorders. Clin Chem Lab Med 2011, 49:409-24.
• [2]Rothermundt M, Ahn JN, Jörgens S: S100B in schizophrenia: an update. Gen Physiol Biophys 2009, 28:F76-81.
• [3]Rothermundt M, Ponath G, Arolt V: S100B in schizophrenic psychosis. Int Rev Neurobiol 2004, 59:445-70.
• [4]Schulte-Herbrüggen O, Hörtnagl H, Ponath G: Distinct regulation of brain-derived neurotrophic factor and noradrenaline in S100B knockout mice. Neurosci Lett 2008, 442:100-3.
• [5]Muller N, Schwarz MJ: The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view. J Neural Transm Suppl 2007, 72:269-80.
• [6]Beumer W, Drexhage RC, De Wit H: Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology 2012. In press
• [7]Schwarz E, Guest PC, Rahmoune H: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry 2012, 17:494-502.1.
• [8]Leonard BE, Schwarz M, Myint AM: The metabolic syndrome in schizophrenia: is inflammation a contributing cause? J Psychopharmacol 2012, 26:33-41.
• [9]Steiner J, Myint AM, Schiltz K: S100B Serum levels in schizophrenia are presumably related to visceral obesity and insulin resistance. Cardiovasc Psychiatry Neurol 2010, 2010:480707.
• [10]Steiner J, Walter M, Guest P: Elevated S100B levels in schizophrenia are associated with insulin resistance. Mol Psychiatry 2010, 15:3-4.
• [11]Streitbürger DP, Arelin K, Kratzsch J: Validating serum S100B and neuron-specific enolase as biomarkers for the human brain - a combined serum, gene expression and MRI study. PLoS One 2012, 7:e43284.
• [12]Steiner J, Westphal S, Schroeter ML: Increased S100B + NK cell counts in acutely ill schizophrenia patients are correlated with the free cortisol index, but not with S100B serum levels. Brain Behav Immun 2012, 26:564-7.
• [13]Muller N, Schwarz M: Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox Res 2006, 10:131-48.
• [14]Zhai J, Cheng L, Dong J: S100B gene polymorphisms predict prefrontal spatial function in both schizophrenia patients and healthy individuals. Schizophr Res 2012, 134:89-94.
• [15]Zhai J, Zhang Q, Cheng L: Risk variants in the S100B gene, associated with elevated S100B levels, are also associated with visuospatial disability of schizophrenia. Behav Brain Res 2011, 217:363-8.
• [16]Dagdan E, Morris DW, Campbell M: Functional assessment of a promoter polymorphism in S100B, a putative risk variant for bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2011, 156B:691-9.
• [17]Suchankova P, Baghaei F, Rosmond R: Genetic variability within the S100B gene influences the personality trait self-directedness. Psychoneuroendocrinology 2011, 36:919-23.
• [18]Saus E, Brunet A, Armengol L: Comprehensive copy number variant (CNV) analysis of neuronal pathways genes in psychiatric disorders identifies rare variants within patients. J Psychiatr Res 2010, 4:971-8.
• [19]Hohoff C, Ponath G, Freitag CM: Risk variants in the S100B gene predict elevated S100B serum concentrations in healthy individuals. Am J Med Genet B Neuropsychiatr Genet 2010, 153B:291-7.
• [20]Roche S, Cassidy F, Zhao C: Candidate gene analysis of 21q22: support for S100B as a susceptibility gene for bipolar affective disorder with psychosis. Am J Med Genet B Neuropsychiatr Genet 2007, 144B:1094-6.
• [21]Liu J, Shi Y, Tang J: SNPs and haplotypes in the S100B gene reveal association with schizophrenia. Biochem Biophys Res Commun 2005, 328:335-41.
• [22]Suchankova P, Klang J, Cavanna C: Is the Gly82Ser polymorphism in the RAGE gene relevant to schizophrenia and the personality trait psychoticism? J Psychiatry Neurosci 2012, 37:122-8.
• [23]Steiner J, Walter M, Wunderlich MT: A new pathophysiological aspect of S100B in schizophrenia: potential regulation of S100B by its scavenger soluble RAGE. Biol Psychiatry 2009, 65:1107-10.
• [24]Falcone T, Fazio V, Lee C: Serum S100B: a potential biomarker for suicidality in adolescents? PLoS One 2010, 5:e11089.
• [25]Zhang XY, Xiu MH, da Chen C: Increased S100B serum levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. J Psychiatr Res 2010, 44:429-33.
• [26]Steiner J, Bernstein HG, Bielau H: S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study. J Psychiatr Res 2008, 42:868-76.
• [27]Ryoun Kim H, Kyung Lee M, Park DB: Increased serum S100B protein in chronic schizophrenic patients in Korea. Clin Chem Lab Med 2007, 45:1561-3.
• [28]Rothermundt M, Ohrmann P, Abel S: Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:361-4.
• [29]Steiner J, Bielau H, Bernstein HG: Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J Neurol Neurosurg Psychiatry 2006, 77:1284-7.
• [30]Rothermundt M, Falkai P, Ponath G: Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol Psychiatry 2004, 9:897-9.
• [31]Wiesmann M, Wandinger KP, Missler U: Elevated plasma levels of S-100b protein in schizophrenic patients. Biol Psychiatry 1999, 45:1508-1511.
• [32]Zhang XY, Xiu MH, Song C: Increased serum S100B in never-medicated and medicated schizophrenic patients. J Psychiatr Res 2010, 44:1236-40.
• [33]Qi LY, Xiu MH, da Chen C: Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics. Neurosci Lett 2009, 462:113-7.
• [34]Schroeter ML, Steiner J: Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders. Mol Psychiatry 2009, 14:235-7.
• [35]Schroeter ML, Abdul-Khaliq H, Krebs M: Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia–original research and meta-analysis. Psychiatry Res 2009, 167:66-72.
• [36]Pedersen A, Diedrich M, Kaestner F: Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1789-92.
• [37]Ehrenreich H, Hinze-Selch D, Stawicki S: Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry 2007, 12:206-20.
• [38]van Beveren NJ, van der Spelt JJ, de Haan L: Schizophrenia-associated neural growth factors in peripheral blood. A review. Eur Neuropsychopharmacol 2006, 16:469-80.
• [39]Schmitt A, Bertsch T, Henning U: Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms. Schizophr Res 2005, 80:305-13.
• [40]Rothermundt M, Ponath G, Glaser T: S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology 2004, 29:1004-11.
• [41]Schroeter ML, Abdul-Khaliq H, Frühauf S: Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophr Res 2003, 62:231-6.
• [42]Lara DR, Gama CS, Belmonte-de-Abreu P: Increased serum S100B protein in schizophrenia: a study in medication-free patients. J Psychiatr Res 2001, 35:11-4.
• [43]Rothermundt M, Missler U, Arolt V: Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol Psychiatry 2001, 6:445-9.
• [44]Gattaz WF, Lara DR, Elkis H: Decreased S100-beta protein in schizophrenia: preliminary evidence. Schizophr Res 2000, 43:91-95.
• [45]Liu Y, Buck DC, Neve KA: Novel interaction of the dopamine D2 receptor and the Ca2+ binding protein S100B: role in D2 receptor function. Mol Pharmacol 2008, 74:371-8.
• [46]Nardin P, Tramontina AC, Quincozes-Santos A: In vitro S100B secretion is reduced by apomorphine: effects of antipsychotics and antioxidants. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1291-6.
• [47]Herrmann AP, Lunardi P, Pilz LK: Effects of the putative antipsychotic alstonine on glutamate uptake in acute hippocampal slices. Neurochem Int 2012. In press
• [48]Steiner J, Schroeter ML, Schiltz K: Haloperidol and clozapine decrease S100B release from glial cells. Neuroscience 2010, 167:1025-31.
• [49]Sen J, Belli A: S100B in neuropathologic states: the CRP of the brain? J Neurosci Res 2007, 85:1373-80.
• [50]Steiner J, Bernstein HG, Bielau H: Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci 2007, 2:8-2.
• [51]Koller E, Schneider B, Bennett K: Clozapine-associated diabetes. Am J Med 2001, 111:716-23.
• [52]American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. DSM–IV–TR. 4 edition. Washington, DC: American Psychiatric Press; 1994.
• [53]Woods SW: Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003, 64:663-667.
• [54]Overall JE, Gorham DR: The brief psychiatric rating scale. Psychol Rep 1962, 10:799-812.
• [55]Andreasen N: Negative symptoms in schizophrenia. Arch Gen Psychiatry 1982, 39:784-788.
• [56]Wilson PWF, D’Agostino RB, Levy D: Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
• [57]Osby U, Correia N, Brandt L: Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr Res 2000, 45(1–2):21-28.
• [58]Spelman LK, Walsh PI, Sharifi N: Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet Med 2007, 24:481-485.
• [59]Choong E, Bondolfi G, Etter M: Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population. J Psychiatr Res 2012, 46:540-8.
• [60]Hughes JR, Hatsukami DK, Mitchell JE: Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986, 143:8.
• [61]van Engelen BG, Lamers KJ, Gabreels FJ: Age related changes of neuron-specific enolase, S-100 protein, and myelin basic protein concentrations in cerebrospinal fluid. Clin Chem 1992, 38:813-816.
• [62]Nygaard O, Langbakk B, Romnera B: Age- and sex-related changes of S-100 protein concentrations in cerebrospinal fluid and serum in patients with no previous history of neurological disorder. Clin Chem 1997, 43:541-543.
• [63]Wiesmann M, Missler U, Gottmann D: Plasma S-100b protein concentration in healthy adults is age- and sex-independent. Clin Chem 1998, 44:1056-1058.
• [64]Gazzolo D, Michetti F, Bruschettini M: Pediatric concentrations of S100B protein in blood: Age- and Sex-related changes. Clin Chem 2003, 49:967-970.
• [65]Dev KK, Mullershausen F, Mattes H: Brain S1P receptors: implication for fingolimod in the treatment of multiple sclerosis. Pharmacol Ther 2008, 117:77-93.
• [66]Gonçalves CA, Leite MC, Guerra MC: Adipocytes as an important source of serum S100B and possible roles of this protein in adipose tissue. Cardiovasc Psychiatry Neurol 2010, 2010:790431.
• [67]Netto CB, Conte S, Leite MC: Serum S100B protein is increased in fasting rats. Arch Med Res 2006, 37:683-6.
• [68]Holtkamp K, Bühren K, Ponath G: Serum levels of S100B are decreased in chronic starvation and normalize with weight gain. J Neural Transm 2008, 115:937-40.
• [69]Barreira TV, Staiano AE, Harrington DM: Anthropometric correlates of total body fat, abdominal adiposity, and cardiovascular disease risk factors in a biracial sample of Men and women. Mayo Clin Proc 2012, 87(5):452-460.
• [70]Meltzer HY, Chai BL, Thompson PA: Effect of scopolamine on the efflux of dopamine and its metabolites after clozapine, haloperidol or thioridazine. J. Pharm. Exp. Ther 1994, 268:1452-1461.
• [71]Konopaske GT, Dorph-Petersen KA, Sweet RA: Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol Psychiatry 2008, 63:759-65.
• [72]Stanwood GD: Protein-protein interactions and dopamine D2 receptor signaling: a calcium connection. Mol Pharmacol 2008, 74:317-9.
• [73]Hearst SM, Lopez ME, Shao Q: Dopamine D2 receptor signaling modulates mutant ataxin-1 S776 phosphorylation and aggregation. J Neurochem 2010, 114(3):706-16.
• [74]Dempsey BR, Shaw GS: Identification of calcium-independent and calcium-enhanced binding between S100B and the dopamine D2 receptor. Biochemistry 2011, 50(42):9056-65.
• [75]Liu J, Wang H, Zhang L: S100B transgenic mice develop features of Parkinson’s disease. Arch Med Res 2011, 42(1):1-7.